Summary
Post-traumatic stress disorder (PTSD) is a severe mental disorder, annually affecting 3.2% of the population with global market-size estimated at €7.5B. Current treatments’ success is marginal, costly, with severe side-effects. GrayMatters is the first to introduce a non-invasive
digital-therapeutics device harnessing brain plasticity to help PTSD patients control abnormal brain-region activity. Our patented innovation uses machine-learning to convert EEG signal to an fMRI-like signal of the amygdala such that patients learn to self-control their amygdala activity
level using affordable EEG-Neurofeedback device. Initial clinical-trials on stress-resilience & PTSD patients showed significant positive clinical results. The founders have 25+ years experience in commercialization, healthcare & technology with several startups exits/IPOs. LOIs
includes top mental-institutes and world-renowned KOLs of PTSD psychiatry. GMH was recently chosen as 1 of 8 innovative companies by Nature magazine.
digital-therapeutics device harnessing brain plasticity to help PTSD patients control abnormal brain-region activity. Our patented innovation uses machine-learning to convert EEG signal to an fMRI-like signal of the amygdala such that patients learn to self-control their amygdala activity
level using affordable EEG-Neurofeedback device. Initial clinical-trials on stress-resilience & PTSD patients showed significant positive clinical results. The founders have 25+ years experience in commercialization, healthcare & technology with several startups exits/IPOs. LOIs
includes top mental-institutes and world-renowned KOLs of PTSD psychiatry. GMH was recently chosen as 1 of 8 innovative companies by Nature magazine.
Unfold all
/
Fold all
More information & hyperlinks
| Web resources: | https://cordis.europa.eu/project/id/190165249 |
| Start date: | 01-09-2022 |
| End date: | 31-08-2024 |
| Total budget - Public funding: | 3 592 625,00 Euro - 2 500 000,00 Euro |
Cordis data
Original description
Post-traumatic stress disorder (PTSD) is a severe mental disorder, annually affecting 3.2% of the population with global market-size estimated at €7.5B. Current treatments’ success is marginal, costly, with severe side-effects. GrayMatters is the first to introduce a non-invasivedigital-therapeutics device harnessing brain plasticity to help PTSD patients control abnormal brain-region activity. Our patented innovation uses machine-learning to convert EEG signal to an fMRI-like signal of the amygdala such that patients learn to self-control their amygdala activity
level using affordable EEG-Neurofeedback device. Initial clinical-trials on stress-resilience & PTSD patients showed significant positive clinical results. The founders have 25+ years experience in commercialization, healthcare & technology with several startups exits/IPOs. LOIs
includes top mental-institutes and world-renowned KOLs of PTSD psychiatry. GMH was recently chosen as 1 of 8 innovative companies by Nature magazine.
Status
SIGNEDCall topic
HORIZON-EIC-2021-ACCELERATOROPEN-01Update Date
09-02-2023
Images
No images available.
Geographical location(s)
